Scholarlink

<p><i>Bacillus coagulans</i> MBBCM9™ is a probiotic strain with potential therapeutic utility, necessitating thorough safety evaluation. This study aimed to assess its dermal and oral toxicity profile following internationally recognized guidelines. Dermal irritation/corrosion potential was evaluated in New Zealand White rabbits (OECD 404). Acute oral toxicity (OECD 425) using a limit dose of 2000&#xa0;mg/kg, and repeated-dose 28-day (OECD 407) and 90-day (OECD 408) oral toxicity studies using doses of 0, 0.65, 35.72, and 74.76&#xa0;mg/kg/day were conducted in Sprague–Dawley rats. Assessments included mortality, clinical signs, body weight, food consumption, hematology, clinical biochemistry, urinalysis, and histopathology. Results indicated that MBBCM9™ was non-irritant and non-corrosive upon dermal application. The acute oral LD50 was determined to be greater than 2000&#xa0;mg/kg. In both the 28-day and 90-day repeated-dose studies, no mortality or significant treatment-related adverse effects were observed in any parameter evaluated, including clinical signs, body weight, food intake, hematological and biochemical markers, or organ pathology, even at the highest dose. The No-Observed-Adverse-Effect Level (NOAEL) for MBBCM9™ was established as 74.76&#xa0;mg/kg/day for both 28 and 90&#xa0;days of oral administration. These comprehensive findings demonstrate a robust safety profile for <i>Bacillus coagulans</i> MBBCM9™, supporting its potential for further development and safe use in human therapeutic or supplementary applications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Unprecedented multi-endpoint safety assessment of Bacillus coagulans MBBCM9™ dermal and oral toxicity in rabbits and rats across diverse exposure periods

  • 期刊论文

  • 发表日期：

    2026年6月19日

查看全文
  • Mruduka Patel,
  • Gaurav Kaushik,
  • Sonal Pandey,
  • Pankita Ahir,
  • Nikhil Gangurde,
  • Nikhil Mudholkar,
  • Sanjeev Acharya

摘要

Bacillus coagulans MBBCM9™ is a probiotic strain with potential therapeutic utility, necessitating thorough safety evaluation. This study aimed to assess its dermal and oral toxicity profile following internationally recognized guidelines. Dermal irritation/corrosion potential was evaluated in New Zealand White rabbits (OECD 404). Acute oral toxicity (OECD 425) using a limit dose of 2000 mg/kg, and repeated-dose 28-day (OECD 407) and 90-day (OECD 408) oral toxicity studies using doses of 0, 0.65, 35.72, and 74.76 mg/kg/day were conducted in Sprague–Dawley rats. Assessments included mortality, clinical signs, body weight, food consumption, hematology, clinical biochemistry, urinalysis, and histopathology. Results indicated that MBBCM9™ was non-irritant and non-corrosive upon dermal application. The acute oral LD50 was determined to be greater than 2000 mg/kg. In both the 28-day and 90-day repeated-dose studies, no mortality or significant treatment-related adverse effects were observed in any parameter evaluated, including clinical signs, body weight, food intake, hematological and biochemical markers, or organ pathology, even at the highest dose. The No-Observed-Adverse-Effect Level (NOAEL) for MBBCM9™ was established as 74.76 mg/kg/day for both 28 and 90 days of oral administration. These comprehensive findings demonstrate a robust safety profile for Bacillus coagulans MBBCM9™, supporting its potential for further development and safe use in human therapeutic or supplementary applications.